595P - Adoption of remote patient monitoring in gastrointestinal oncology: A real-world experience from 1822 patients across 47 centers in France and Belgium

Background

Remote patient monitoring (RPM) using electronic Patient Reported Outcomes (ePROs) offers a unique opportunity to detect actionable symptoms commonly experienced by patients undergoing anticancer therapy. RPM demonstrated effectiveness in reducing morbidity, while improving quality of life through multiple phase 3 trials. Therefore, the European Society for Medical Oncology (ESMO) recommended the use of RPM based on ePROs in routine care in the 2022 clinical practice guidelines. However, the patient adherence and the benefits of RPM in gastrointestinal (GI) oncology remain largely unknown.

Methods

RPM pathway includes four steps: (i) medical prescription, (ii) patients onboarding by a nurse, (iii) weekly collection of tailored symptoms survey, (iv) severe (grades 3-4) or worsening symptoms (moving from a grade 0 to 2) trigger an alert notification to the care team. Data from all patients treated for GI malignancies and included in the RPM solution between January 2022 and January 2024 were analyzed.

Results

In this study, a total of 1822 patients across 47 healthcare centers in France and Belgium were included. The mean age of the cohort was 66 years (20-93), with males forming 57% and females 43% of the population. The most prevalent primary tumor sites were colorectal (52%), pancreas (23%), stomach (6%), oesophagus (6%), liver (5%) and other (8%). Disease status was localized in 48% and advanced/metastatic in 52%. After three months of monitoring, adherence to weekly questionnaires was 77%. The most common symptoms triggering alerts were pain (57%), diarrhea (40%), nausea (37%), and decline in performance status (37%). After the alerts, assessment of symptoms within two weeks showed a proportion of 92% with at least 1 grade improvement, and in 78% showing an improvement of 2 to 3 grade points from the PRO-CTCAE® measurement system.

Conclusions

The implementation of an RPM pathway in routine care for patients with gastrointestinal malignancies is feasible, associates with high patient adherence, and results in meaningful clinical benefit. These findings reinforce the importance of integrating RPM in GI oncology as a standard of care in routine clinical practice.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Resilience.

Funding

Has not received any funding.

Disclosure

P. Artru: Financial Interests, Personal, Advisory Board: AstraZeneca, MSD, Roche, Servier, Pierre Fabre, BMS, merck serono, Takeda; Financial Interests, Personal, Invited Speaker: Amgen. S. Javed: Financial Interests, Personal, Advisory Board: AstraZeneca. T. Papazyan: Financial Interests, Personal, Full or part-time Employment: Resilience. C. Ferté: Financial Interests, Personal, Full or part-time Employment: Resilience. M. Autheman: Financial Interests, Personal, Full or part-time Employment: Resilience. M.P. Ducreux: Financial Interests, Personal, Invited Speaker: Roche, Amgen, Pierre Fabre, Merck Kga, Pfizer, Bayer, Lilly, Servier, MSD, BeiGene; Financial Interests, Personal, Advisory Board: Roche, Basilea, Pierre Fabre, Boehringer, Rafael, Servier, Zymeworks, Ipsen, Bayer, HalioDX, Lilly, GSK, Daiichi Sankyo, MSD, Servier, BeiGene; Financial Interests, Institutional, Advisory Board: AstraZeneca; Financial Interests, Institutional, Funding, Partial funding of a trial evaluating the role of bevacizumab in NET: Roche; Financial Interests, Institutional, Funding, Partial funding of a trial evaluating the role of steptozotocin in NET: Keocyt; Financial Interests, Institutional, Local PI: Rafael, Amgen; Financial Interests, Institutional, Funding: Bayer; Other, Wife Head of the Oncology Business Unit: Sandoz France. All other authors have declared no conflicts of interest.